Should higher vancomycin trough levels be targeted for invasive community-acquired methicillin-resistant Staphylococcus aureus infections in children?

Pediatr Infect Dis J. 2010 Apr;29(4):368-70. doi: 10.1097/INF.0b013e3181c52a04.

Abstract

Methicillin-resistant Staphylococcus aureus isolates with vancomycin minimal inhibitory concentrations (MICs) >or=1.5 microg/mL have been associated with poorer clinical outcomes and treatment failures in adults. We evaluated vancomycin MICs in 71 invasive pediatric community-acquired MRSA isolates from 2004 to 2008, using the E-test micromethod and the E-test macro-method. The modal MIC by micromethod was 1.5 microg/mL, and median vancomycin MICs did not increase over time.

Publication types

  • Clinical Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use
  • Child
  • Community-Acquired Infections / drug therapy*
  • Community-Acquired Infections / microbiology
  • Humans
  • Methicillin-Resistant Staphylococcus aureus / drug effects*
  • Microbial Sensitivity Tests / methods
  • Microbial Sensitivity Tests / standards*
  • Staphylococcal Infections / drug therapy*
  • Staphylococcal Infections / microbiology
  • Vancomycin / pharmacology*
  • Vancomycin / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Vancomycin